Latest Articles

Publication Date
Advanced Management of Severe Adenomyosis in IVF: A Personalized Approach With Extended GnRH Agonist and Letrozole Therapy.

The objective of this study is to evaluate the effectiveness of prolonged GnRH agonist (GnRH-a) suppression combined with letrozole and intensive luteal phase support in a patient with severe adenomyosis …

Published: March 9, 2026, midnight
Effects of E2/ERβ on follicular granulosa cells and on AMH/Smad signalling in endometriosis.

Patients with endometriosis have greater risk of infertility, which is associated with compromised ovarian function. Dysfunction in follicular granulosa cells and hyperactivation of oestrogen receptor beta (ERβ) are evident in …

Published: March 6, 2026, midnight
Bladder Endometriosis Resolved by Robotic-Assisted Partial Cystectomy.

This is a case report of a 31-year-old G1P1 with deep infiltrating endometriosis (DIE) of the bladder. She presented with bladder spasms, dysuria, and urinary frequency that worsened during her …

Published: March 2, 2026, midnight
Integrating ultrasound findings and extreme CA-125 elevation in the diagnosis of spontaneous endometrioma rupture: a case report.

Introduction: Spontaneous rupture of an endometrioma may result in life-threatening condition. Detection and prompt treatment are necessary. Presentation of Case: A 27-year-old woman presented to labor and delivery unit with …

Published: Feb. 28, 2026, midnight
GnRH Receptor Antagonists Market Size to Hit USD 5.25 Billion by 2035 - Precedence Research

GnRH Receptor Antagonists Market Size to Hit USD 5.25 Billion by 2035 Precedence Research

Published: Feb. 27, 2026, 2:45 p.m.
Cell Subtypes and Gene Dysfunction in Ovarian Endometriosis Before and After GnRHa Treatment Revealed by Single-Cell RNA Sequencing.

Fibrosis, angiogenesis and chronic inflammation are the intrinsic characteristics of endometriosis. It is accompanied by significant changes in the cell composition of both ectopic and eutopic endometrial tissues, occurring both …

Published: Feb. 13, 2026, midnight
Dydrogesterone and Letrozole Combination for the Treatment of Endometriosis: A Mechanism-Based Therapeutic Approach.

Endometriosis is a complex, estrogen-dependent disease with limited effective treatments that often focus on symptom management rather than addressing the underlying pathology. Current therapies, such as progestins and GnRH agonists, …

Published: Feb. 13, 2026, midnight
Atypical gelation of Elagolix sodium in aqueous media: Mechanistic insights and Inhibition via coamorphization.

Elagolix sodium (ELS), a non-peptide oral gonadotropin-releasing hormone receptor (GnRH) antagonist approved for the treatment of endometriosis-associated pain, displays atypical gelation in aqueous environments along with challenging physical properties such …

Published: Feb. 12, 2026, midnight
Impact of hormonal treatments for endometriosis on the reproductive microbiome: a systematic review.

The reproductive microbiome plays a key role in disease progression and fertility in women with endometriosis. Vaginal and endometrial dysbiosis has been increasingly linked to inflammation, impaired reproductive outcomes, and …

Published: Feb. 12, 2026, midnight
Safety, Pharmacokinetics, and Sex Hormone Suppression of LY01021 versus Relugolix: A Single- and Multiple-Dose Escalation Study.

LY01021 is a novel oral small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of various sex hormone-dependent disorders. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), …

Published: Feb. 5, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!